Onset and Duration of Mometasone by Oscillometry and Spirometry
Onset and Duration of Mometasone by Oscillometry and Spirometry
Inhaled corticosteroids (ICS) are appreciated for their long term anti-inflammatory effects
 in chronic asthma. However, they also have largely unappreciated early effects when initiated
 as a controller therapy in a steroid-naïve population. Impulse oscillometry might reveal such
 an early effect better than spirometry. The investigators sought to examine the onset of
 action and sustained effects over 4 weeks treatment of mometasone furoate as measured by
 Impulse Oscillometry System (IOS) versus spirometry.
Inclusion Criteria:

 -  Age between 18-65 years inclusive.

 -  Written informed consent (conducted according to the GCP and ICH guidelines) to
 participate in the study. Ability to comply with all study requirements.

 -  Mild to moderate persistent asthma with symptoms at least 2 times per week, managed by
 as-needed SABA only.

 -  A 35% or greater improvement in small airway dysfunction defined by IOS AX after
 inhaled SABA.

 -  Allergic response to one or more common allergens at screening via skin test.

 -  Male, or female of childbearing potential using a medically approved birth control
 method.

 -  Evidence of SAD manifested by an index of peripheral airway reactance of > 10.5 cm
 H2O/L (3 times the upper limit of adult normal).

 -  Symptoms of airflow obstruction (i.e. dyspnea on exertion greater than peers at
 similar exercise levels, wheeze, or cough > 3 weeks without respiratory infection, or
 nocturnal dyspnea, and use of SABA > 2 times per week)

 Exclusion Criteria:

 -  Subjects with severe persistent asthma and/or subjects taking inhaled or systemic
 corticosteroids or long acting beta agonists (LABA).

 -  Subjects < 18 years of age or > 65 years.

 -  Pregnant or lactating females.

 -  History of diabetes.

 -  Acute infections within 4 weeks prior to Screening.

 -  Concurrent medical condition that might interfere with the interpretation of efficacy
 and safety data during the study.

 -  Contraindications and warnings according to the specific label for Asmanex.

 -  Chronic inhaled or systemic corticosteroid treatment (> 7 consecutive days of
 treatment) within 30 days prior to Screening.

 -  Investigational drug treatment within 30 days prior to Screening. Treatment with any
 drug with a known and frequent toxicity to a major organ system within the past 60
 days.